Activation of ryanodine receptor/Ca2+ release channels downregulates CD38 in the Namalwa B lymphoma  by McCarthy, Tommie V. et al.
Activation of ryanodine receptor/Ca2þ release channels downregulates
CD38 in the Namalwa B lymphoma
Tommie V. McCarthy, Sue Datar, John J. Mackrill
Department of Biochemistry, Biosciences Institute, National University of Ireland, University College Cork, College Road, Cork, Ireland
Received 15 August 2003; accepted 15 September 2003
First published online 7 October 2003
Edited by Felix Wieland
Abstract CD38 is a multifunctional ectoenzyme that catalyses
formation of cyclic ADP ribose (cADPr), a second messenger
that opens ryanodine receptor (RyR) Ca2+ channels. Despite its
importance in signal transduction processes, little is known
about the mechanisms regulating CD38 expression levels. In
the current study, ryanodine stimulation of Ca2+ release in Na-
malwa cells decreased both CD38 protein abundance and cy-
clase activity. Reductions in cyclase activity were prevented by
RyR antagonists, by lysosomal blockers, though not by calpain
or proteasomal inhibitors. These ¢ndings indicate a novel neg-
ative feedback mechanism between RyR channel activity and
CD38 abundance acts in cADPr signal transduction.
+ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
CD38 is a multifunctional ectoenzyme expressed in a wide
range of cell types, including lymphocytes, pancreatic L cells,
neurones and smooth muscle cells [1]. This enzyme is a type II
plasma membrane protein that catalyses formation of cyclic
ADP ribose (cADPr) from extracellular nicotinamide adenine
dinucleotide (NAD). Dimerisation of CD38 [2] and/or inter-
nalisation of membrane vesicles bearing this enzyme [3,4] fa-
cilitates entry of cADPr into the cytoplasm, where this cyclic
nucleotide acts as a second messenger, opening ryanodine
receptor (RyR)/Ca2þ release channels in the endoplasmic re-
ticulum, thereby increasing cytosolic free Ca2þ [Ca2þ]c. Eleva-
tions in [Ca2þ]c subsequently regulate a plethora of cellular
processes, including proliferation, gene expression, secretion,
motility, necrosis and apoptosis [5]. Despite its signi¢cance in
signal transduction processes, little is known about mecha-
nisms regulating CD38 protein abundance. Interleukin-4
downregulates CD38 in a human B cell line, via a serine/
threonine protein kinase-dependent pathway [6]. In renal me-
sangial cells, CD38 is upregulated by tumour necrosis factor-
K, interleukin-1L and all-trans-retinoic acid [7]. In a variety of
cell types, activation of CD38 by NAD, or by antibody-medi-
ated cross-linking, decreases surface expression of the cyclase
by a mechanism dependent on membrane internalisation
[3,4,8,20].
In mammals, the RyR family consists of three isoforms of
cation channel that release Ca2þ from intracellular stores,
such as the endoplasmic and sarcoplasmic reticulum.
Although these channel proteins were originally characterised
in tissues where they are present at high levels, namely skeletal
muscle (RyR1) and heart (RyR2), they are also expressed in a
broad range of non-muscle cells [9^12,28]. Despite being piv-
otal in striated muscle excitation^contraction coupling, the
roles of RyRs in other cell types have not been extensively
de¢ned. B lymphocyte cell lines and CD19+ B cells isolated
from blood express functional RyR1 channels that are acti-
vated in response to B cell receptor cross-linking [12]. Phar-
macological activation of B cell RyRs using the agonists
4-chloro-meta-cresol (CmC) or ca¡eine increases interleukin-
1L secretion [13], indicating that Ca2þ signalling via these
channels plays a role in regulation of immune response.
Namalwa Burkitt’s lymphoma, a CD19+ model of the ma-
ture human B cell, expresses CD38 and has been used exten-
sively in the investigation of the catalytic properties of this
cyclase [3]. In spite of this, little is known about the relation-
ships between CD38 and RyR Ca2þ signalling in this B lym-
phocyte cell line. In the current study, the presence of func-
tional RyRs in Namalwa cells and the biological consequences
of their prolonged activation were analysed [14]. In particular,
the relationships between CD38 activity and RyR-mediated
Ca2þ release were investigated. For the ¢rst time, it was dem-
onstrated that: (1) Namalwa B cells express the RyR1 iso-
form, which mobilises Ca2þ in response to millimolar CmC
or nanomolar ryanodine; (2) prolonged (24 h) stimulation of
Namalwa cells with ryanodine results in a dramatic reduction
in CD38 protein level, GDP ribosyl cyclase activity and Ca2þ
mobilisation elicited by extracellular NAD; (3) these e¡ects
are speci¢c, since levels of surface IgM W chain are not in£u-
enced by ryanodine treatment; (4) CD38 downregulation is
abrogated by procaine or dantrolene, RyR antagonists; and
(5) RyR-mediated CD38 downregulation is dependent on the
lysosomal pathway of proteolysis, since this e¡ect is blocked
by pretreatment with ammonium chloride or chloroquine,
though not by calpain and proteasome inhibitors. These ob-
servations indicate a novel negative feedback mechanism op-
erates in B lymphocyte CD38 Ca2þ signalling: prolonged ac-
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tivation of RyRs resulting in lysosomal downregulation of the
cADPr producing ectoenzyme.
2. Materials and methods
2.1. Materials
A549 lung epithelial carcinoma, Jurkat T lymphoma, Namalwa
Burkitt’s lymphoma and SHSY5Y neuroblastoma cell lines were cul-
tured according to the protocols of the European Collection of Ani-
mal Cell Cultures. Ryanodine, CmC, human IgM, anti-human IgM W
chain peroxidase conjugate and a⁄nity-puri¢ed goat anti-human IgM
W chain were from Merck. Mouse anti-CD38 monoclonal antibody
AT1 was purchased from Santa Cruz Biotech. Fluo-3-acetoxymethyl
ester (Fluo-3AM) was from Molecular Probes. Aplysia californica
ribosyl cyclase, NAD, nicotinamide guanine dinucleotide (NGD)
and protease inhibitors were from Sigma-Aldrich. SuperSignal En-
hanced Chemiluminescence reagents were from Pierce. All other re-
agents were of analytical grade or better.
2.2. Measurement of [Ca2+]c using Fluo-3
Namalwa B cells were harvested by centrifugation at 1000Ug for
5 min, washed once with Krebs^Henseleit bu¡er (KHB: 120 mM
NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM
NaHCO3, 10 mM glucose, 1 mM probenecid, 5 mM HEPES pH
7.2) containing 2 mM CaCl2, then they were resuspended at a density
of 6U106 cells/ml in KHB containing 2 mM CaCl2 and 5 WM of Fluo-
3AM. Following incubation for 1 h at room temperature in the dark,
Namalwa cells were washed twice with KHB, then they were resus-
pended in 3 ml of KHB (2U106 cells/ml) containing 2 mM CaCl2, or
in some cases 0.5 mM EGTA, in a stirred £uorimetry cuvette at 37‡C.
Fluo-3 £uorescence (490 nm excitation/530 nm emission) was moni-
tored using either a Perkin-Elmer LS50B or a Wallac Varian Eclipse
luminescence spectrometer. At the end of all experiments, £uorescence
measurements were calibrated to [Ca2þ]c levels by addition of 1%
Triton X-100, then 4 mM EGTA, according to the protocol of Gryn-
kiewicz et al. [15].
2.3. Miscellaneous
Reverse transcription polymerase chain reaction (RT-PCR) was
employed to determine the RyR isoform expression pro¢le of Namal-
wa cells, using the protocol of Sei et al. [12], as modi¢ed by Hosoi et
al. [16]. The NGD cyclase activity of Namalwa cells was assayed using
the protocol of Grae¡ et al. [17]. In brief, cells (0.5U106) were lysed in
500 Wl of 20 mM Tris^HCl pH 7.4 by ¢ve passes through a 19 gauge
needle, then were incubated with 100 WM of NGD for 1 h at 37‡C.
Reactions were stopped by addition of 10 Wl of 50% trichloroacetic
acid and the £uorescent product (cyclic GDP ribose, cGDPr) mea-
sured at excitation/emission wavelengths of 300 nm/410 nm. Concen-
trations of cGDPr were determined from £uorescence values using a
standard curve generated using known amounts of cGDPr, produced
using A. californica ADP ribosyl cyclase. For protease inhibition ex-
periments, cells were pretreated with N-acetyl-Leu-Leu-Met-al
(ALLM), calpain inhibitor II, chloroquine or Z-Leu-Leu-Leucinal
(MG132) for 30 min, then were pelleted and resuspended in fresh
culture medium without inhibitor prior to 24 h incubation with rya-
nodine. This was necessary because prolonged treatment of Namalwa
lymphocytes with these inhibitors signi¢cantly increased cell death.
Other inhibitors were added at the same time as ryanodine and co-
incubated for 24 h. Protein concentrations were determined using the
method of Bradford [19], using bovine serum albumin as a standard.
Numerical data are expressed as mean valuesS S.E.M. and n was the
number of experiments performed. Data were ¢tted to the Hill equa-
tion using GraphPad Prism software. Di¡erences between samples
were analysed using a paired Student’s t-test using Microsoft Excel.
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Fig. 1. Namalwa B lymphoma cells express functional RyR1 Ca2þ
channels. A: Namalwa cells express RyR1 mRNA. Shown are aga-
rose electrophoresis gels of PCR products ampli¢ed from cDNA
from various cell lines using RyR isoform-speci¢c primer sets. PCR
products formed are 1112 bp for RyR1, 1083 bp for RyR2 and
1015 bp for RyR3. B: The RyR agonist CmC increases [Ca2þ]c in
Namalwa cells by releasing this ion from intracellular stores. In the
presence of 2 mM extracellular Ca2þ (black trace), addition of
5 mM CmC (arrow) increased [Ca2þ]c from a resting level of 83S 5
nM (n=25) to a peak of 535S56 nM (n=5). In nominally Ca2þ-
free extracellular medium (0.5 mM extracellular EGTA, grey line),
5 mM CmC elevated [Ca2þ]c from 39S 4 nM (n=5) to a maximum
of 207S 34 nM (n=5). C: Ryanodine causes a sustained increase in
[Ca2þ]c in Namalwa B cells that can be blocked with the RyR an-
tagonist procaine. Addition of 100 nM ryanodine (arrow) to cells
(2 mM CaCl2 in medium) increased [Ca2þ]c from 91S 8 nM (n=3)
at rest to a peak of 217S 14 nM (n=3) after 5 min of ryanodine
addition. Preincubation of the cells with 10 mM procaine, a RyR
antagonist, signi¢cantly (P6 0.005) reduced this maximum elevation
in [Ca2þ]c to 115S9 nM (n=3) after 5 min of ryanodine addition,
from a basal level of 71S 11 nM (n=3).
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3. Results and discussion
Namalwa Burkitt’s lymphoma, a model of the mature hu-
man B lymphocyte, expresses RyR/Ca2þ release channels. Ef-
forts to identify the subtype(s) of RyR expressed in Namalwa
cells by probing Western blots of cell lysates with a range of
isoform-selective antisera [9,10] were unsuccessful, possibly as
a result of the very low relative abundance of these proteins in
B lymphocytes [12]. Consequently, RyR isoform-speci¢c RT-
PCR [19] was employed to identify the subtype(s) of RyR
expressed in Namalwa cells. Using this technique it was found
that like A549 epithelial cells [28], Namalwa lymphocytes ex-
press detectable levels of RyR1 mRNA only (Fig. 1A), in
contrast to Jurkat T cells that possess RyR2 and RyR3 [12],
and SHSY5Y neuroblastoma cells that have RyR2 [9]. This
observation is discrepant from data presented by Hosoi et al.
[16], who report that Namalwa cells do not express any RyR
mRNA. The reasons for this di¡erence are unclear, although
optimal MgCl2 concentrations for ampli¢cation of RyR
cDNA in our laboratory were distinct from those employed
by Sei et al. [12]. Type 1 RyR expressed in Namalwa B lym-
phocytes forms functional Ca2þ release channels. Stimulation
of these cells with a maximal concentration (5 mM) of the
RyR agonist CmC leads to an increase in [Ca2þ]c that persists
in EGTA-bu¡ered extracellular medium (Fig. 1B), indicating
that this ion is released from intracellular stores. Namalwa
cell [Ca2þ]c responses to CmC are dose-dependent, displaying
a half-maximal e¡ective concentration of 0.7 S 0.1 mM (n=3)
and a Hill slope of 2.7 S 0.2 (n=3). These parameters are
similar to those reported for CmC-induced Ca2þ responses
in normal Epstein^Barr virus-immortalised human B cells
[13]. Prolonged exposure (s 60 min) of Namalwa cells to
CmC concentrations greater than 2 mM resulted in a signi¢-
cant increase in the number of trypan blue-permeable cells
that was independent of Ca2þ mobilisation, since it could
not be blocked by the RyR antagonists dantrolene or pro-
caine (data not shown). Consequently, in order to examine
the consequences of long-term RyR activation in Namalwa
Fig. 2. Chronic stimulation of Namalwa B cells with ryanodine
leads to downregulation of the cADPr-generating enzyme CD38.
Namalwa cells were treated for 24 h with 1% DMSO (lane 1), 100
nM ryanodine (lane 2), or 100 nM ryanodine plus 1 mM procaine
(lane 3). Cell lysates (50 Wg protein/lane) were then resolved on 10%
reducing sodium dodecyl sulfate^polyacrylamide gel electrophoresis,
then either (A) stained with Coomassie R250 or transferred onto ni-
trocellulose and immunostained with (B) 1:1000 anti-human IgM
W chain or (C) 5 Wg/ml anti-CD38 monoclonal antibody AT1. Data
shown are representative of three independent experiments.
Fig. 3. Chronic ryanodine stimulation of Namalwa cells results in a
decrease in [Ca2þ]c rises triggered by extracellular NAD. A: Follow-
ing incubation with either 1% DMSO (solid black trace), 100 nM
ryanodine (broken black line) or 100 nM ryanodine plus 1 mM pro-
caine (solid grey line), Namalwa cell [Ca2þ]c responses to extracellu-
lar NAD (5 mM, arrow) were monitored under nominally Ca2þ-free
conditions. Chronic ryanodine stimulation signi¢cantly (P6 0.01) re-
duced [Ca2þ]c responses to extracellular NAD, from a peak change
in [Ca2þ]c of 56S5 nM in DMSO-pretreated cells to 29.1S 0.5 nM
in ryanodine-pretreated lymphocytes. Procaine prevented this de-
crease, with NAD causing a change of [Ca2þ]c of 51S 4 nM in rya-
nodine-plus procaine-pretreated cells (n=3 in all cases). B: Long-
term (24 h) treatment of Namalwa cells with 1% DMSO (‘DMSO’),
100 nM ryanodine (‘Ry’), or 100 nM ryanodine plus 1 mM pro-
caine (‘Ry plus pro’) did not alter their responsiveness to CmC.
Shown are the peak [Ca2þ]c rises in these three groups following
stimulation with 1 mM CmC (n=4 in all cases).
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B lymphocytes, cells were stimulated with 100 nM ryanodine,
which had no signi¢cant e¡ect on viability over a 24 h period.
Ryanodine (100 nM) triggered a sustained increase in [Ca2þ]c
that could be blocked by preincubation with procaine
(Fig. 1C).
Prolonged (24 h) incubation of Namalwa B lymphocytes
with 100 nM ryanodine had no signi¢cant e¡ect on cell via-
bility, proliferation, amount of total cellular protein, or quan-
tity of secreted protein (data not shown). However, 24 h rya-
nodine stimulation drastically reduced CD38 abundance in
Namalwa cells (Fig. 2C), despite having no detectable e¡ect
on surface IgM W chain levels (Fig. 2B). Downregulation of
CD38 could be abrogated using the RyR antagonist procaine
(Fig. 2C). Since CD38 is capable of synthesising the Ca2þ-
mobilising second messenger cADPr from NAD, it was antici-
pated that downregulation of this enzyme by chronic RyR
activation would inhibit [Ca2þ]c rises stimulated by extracel-
lular NAD. As expected, 24 h ryanodine treatment signi¢-
cantly decreased Namalwa B cell responses to NAD, this ef-
fect being prevented by coincubation with the RyR antagonist
procaine (Fig. 3A). These ¢ndings are not a consequence of
ryanodine or procaine remaining within cells following 24 h
exposure and washing steps, or of other alterations in RyR
function, since there were no signi¢cant di¡erences between
dimethyl sulphoxide (DMSO)-treated, ryanodine-treated, or
ryanodine- plus procaine-treated Namalwa cells in the magni-
tude of [Ca2þ]c rises triggered by 1 mM CmC (Fig. 3B). This
indicates that CD38 downregulation by chronic ryanodine
treatment has direct negative impact on Ca2þ signalling in
Namalwa cells, rather than being a consequence of modi¢ed
RyR function.
To quantify CD38 activity following prolonged RyR stim-
ulation, formation of £uorescent cGDPr from non-£uorescent
NGD was monitored. Using this assay, it was found that
ryanodine treatment had a half-maximal e¡ect on NGD ribo-
syl cyclase activity in Namalwa cells after 3.9 S 0.8 h (n=3)
and was complete (40S 5% of original activity, n=3) after
V18 h. Consequently, cyclase assays were performed 24 h
after ryanodine treatment. The GDP ribosyl cyclase assay
was used to investigate the mechanisms responsible for
CD38 downregulation in ryanodine-treated Namalwa cells.
Procaine and the structurally unrelated RyR antagonist dan-
trolene blocked ryanodine-induced loss of cyclase activity (Ta-
ble 1). Inhibitors of the calpain family of Ca2þ-dependent
cysteine proteases, ALLM and calpain inhibitor II, could
not prevent reduction in Namalwa NGD cyclase activity
caused by ryanodine. Analysis of the primary structure of
human CD38 using the PEST¢nd algorithm (http://www.
at.embnet.org/embnet/tools/bio/PEST¢nd/) supports this ob-
servation, since no strong candidate calpain cleavage sites
[18] were detected in this protein. Pretreatment of Namalwa
cells with the proteasome inhibitor MG132 had no discernible
e¡ect on loss of CD38 activity. However, lysosomotropic
agents blocked ryanodine-stimulated loss of CD38 in Namal-
wa lymphocytes, since there was no signi¢cant di¡erence in
cyclase activity between cells treated with ammonium chloride
or chloroquine and cells treated with these compounds plus
ryanodine (Table 1).
The data reported here indicate that prolonged incubation
of Namalwa cells with ryanodine, at concentrations that cause
sustained Ca2þ release via RyRs, downregulates CD38 protein
via the lysosomal degradative pathway. Since CD38 is the key
enzyme in mammalian cells responsible for the synthesis of
cADPr [1], an RyR-activating second messenger, its downre-
gulation represents a potential negative feedback mechanism
in Ca2þ signal transduction processes. In this report, it is
demonstrated for the ¢rst time that RyR activity can drive
lysosomal degradation of CD38, since ryanodine-stimulated
increases in [Ca2þ]c precede any reduction in the activity or
abundance of this enzyme. Furthermore, Namalwa cell
[Ca2þ]c elevations in response to extracellular NAD are dimin-
ished following chronic ryanodine stimulation, without any
detectable decrease in RyR function. Proteolytic steps in neg-
ative feedback mechanisms that regulate Ca2þ signal trans-
duction processes are not unprecedented. Chronic stimulation
of a variety of cell types with hormones that cause sustained
elevations in cytosolic inositol 1,4,5-trisphosphate levels trig-
gers degradation of inositol 1,4,5-trisphosphate receptor/Ca2þ
release channel proteins by the ubiquitin/proteasomal path-
way [21,22]. RyRs are potentially regulated by this degrada-
tive system, since they are associated with a proteasomal rec-
ognition subunit S5a [23].
Table 1
E¡ect of protease inhibitors or RyR antagonists on Namalwa NGD ribosyl cyclase activity following chronic ryanodine stimulation
Treatment Cyclase activity
(nmol cGDPr formed/mg protein/minSS.E.M.)
P versus no ryanodine
(‘3’ vs. ‘+’)
n
DMSO 3 1.62 ( S 0.19) 4
DMSO + 0.64 ( S 0.07) 0.003 4
50 WM dantrolene 3 1.65 ( S 0.11) 3
50 WM dantrolene + 1.56 ( S 0.18) NS 3
1 mM procaine 3 1.32 ( S 0.09) 3
1 mM procaine + 1.38 ( S 0.04) NS 3
100 WM chloroquine 3 1.46 ( S 0.17) 3
100 WM chloroquine + 1.60 ( S 0.21) NS 3
10 mM NH4Cl 3 1.21 ( S 0.10) 4
10 mM NH4Cl + 1.47 ( S 0.08) NS 4
50 WM ALLM 3 1.39 ( S 0.18) 3
50 WM ALLM + 0.67 ( S 0.13) 0.031 3
50 WM calpain inhibitor II 3 1.33 ( S 0.10) 3
50 WM calpain inhibitor II + 0.48 ( S 0.05) 0.001 3
50 WM MG132 3 1.97 ( S 0.19) 3
50 WM MG132 + 1.01 ( S 0.08) 0.010 3
Namalwa cells were treated for 24 h in the presence (‘+’) or absence (‘3’) of 100 nM ryanodine plus protease inhibitors or RyR antagonists.
Cellular NGD ribosyl cyclase activity was then measured as described in Section 2. Di¡erences between ryanodine-treated and untreated activ-
ities were compared using a paired Student’s t-test. NS, not signi¢cantly di¡erent, Ps 0.05.
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Several candidate mechanisms might underlie enhancement
of lysosomal degradation of CD38 by RyR-mediated in-
creases in [Ca2þ]c. Endosome fusion is a Ca2þ-dependent
event, regulated by the Ca2þ binding protein calmodulin
[24]. Membrane fusion events are stimulated by inositol
1,4,5-trisphosphate receptor-mediated Ca2þ release from in-
tracellular stores [25]. By analogy, RyR channel opening
might promote endosome/lysosome fusion, thereby increasing
proteolysis of proteins degraded via the lysosomal pathway.
Activation of RyRs also stimulates translocation of mem-
brane vesicles, as observed in the transport of aquaporin
2-bearing membranes triggered by vasopressin in inner medul-
la collecting duct cells [26]. Finally, 17L-estradiol causes an
increase in [Ca2þ]c in mollusc blood cells. This [Ca2þ]c eleva-
tion promotes translocation of Ca2þ-dependent phospholipase
A2 from the cytosol to membranes, which leads to an increase
in lysosomal volume and proteolytic activity [27]. Whatever
the basis of enhanced lysosomal turnover of CD38 by RyR
activation, this process potentially represents a key negative
feedback pathway in cADPr/Ca2þ signal transduction.
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